PXS-4728A is a potent and selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A), which plays a key role in regulating signaling pathways in the brain, particularly in the striatum. Due to its ability to modulate dopamine and glutamate neurotransmission, it has been investigated for the treatment of psychiatric and neurological disorders such as schizophrenia, Huntington’s disease, and other conditions involving basal ganglia dysfunction. Its high selectivity allows for targeted action with potentially fewer side effects compared to broad-acting antipsychotics. PXS-4728A has served as a valuable tool compound in preclinical research to understand PDE10A's role in cognition, motivation, and motor control, supporting the development of novel therapeutics for central nervous system disorders.